(37) has confirmed the existence of two LCNEC subtypes, one (type II) characterized by the concurrent inactivation of TP53 and RB1 (42%) and one (type I) with TP53 and STK11/KEAP1 alterations (37%) (Table 1). This evidence concerns the gene TP53 and large cell neuroendocrine carcinoma.